The Desired Position for FY2025 under EWAY 2025
First written in FY2016. 5 of 14 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2021: 1 of 7 companies on the "Worse" side.
1 other company's latest entry also says "Reframed".
- FY2026ReframedAnnual report
「Beginning in FY2026, we will formulate numerical and execution plans on a 3-year basis and review them annually on a rolling basis.」
From fiscal 2026, the operating framework for EWAY Future & Beyond was reorganized into a system of annually rolling 3-year numerical and execution plans. - FY2025RestatedAnnual report
「The group launched its medium-term management plan, “EWAY Future & Beyond,” in April 2021.」
EWAY Future & Beyond remains the foundation of management, with dementia, oncology, global health, human capital value and financial strategy being advanced under the EWAY Future and EWAY Beyond framework. - FY2024AdvancedAnnual report
「In 2023, we established new materiality issues to efficiently realize social good through the hhc ecosystem. In addition to realizing social good in the areas of dementia, oncology and global health, we identified maximizing human capital value and financial strategy as material issues, and set and identified long-term targets, KPIs and risks toward FY2030.」
Under EWAY Future & Beyond, dementia, oncology and global health, together with human capital value and financial strategy, were organized as material issues, with long-term targets, KPIs and risks set toward FY2030. - FY2023AdvancedAnnual report
「In October 2022, we revamped our R&D organization, and the DHBL structure became fully operational.」
Under EWAY Future & Beyond, the R&D organization was revamped into DHBL and moved into the execution phase, focusing on 5 drug discovery domains. - FY2022RestatedAnnual report
「In April 2021, the group launched “EWAY Future & Beyond” as a new medium-term management plan following “EWAY Current,” which began in FY2016.」
The group continues to implement EWAY Future & Beyond, under which EWAY Future covers FY2021–FY2025 and EWAY Beyond begins in FY2026, while it develops business models based on hhc eco and EUP. - FY2021ReframedAnnual report
「In April 2021, the group launched “EWAY Future & Beyond” as a new medium-term management plan following “EWAY Current,” which began in FY2016.」
The group moved from EWAY Current/EWAY 2025 to a plan comprising EWAY Future for FY2021–FY2025 and EWAY Beyond from FY2026 onward. It also stated that it would not set medium- to long-term numerical targets for revenue or profit, instead refining its annual business plans. - FY2020ReframedAnnual report
「In the latter half of “EWAY 2025,” referred to as “EWAY FUTURE,” we expect growth exceeding that of the first half, driven by contributions to patients from next-generation dementia treatments in which we have continued to make active R&D investments under a partnership model, and from the combination therapy of Lenvima and the anti-PD-1 antibody Keytruda targeting cancers with high unmet medical needs.」
The latter half of EWAY 2025 is called “EWAY FUTURE,” with growth expected from next-generation dementia treatments and Lenvima combination therapies. - FY2020AdvancedAnnual report
「As for the profit targets—operating profit of around ¥102.0 billion, profit for the year of around ¥74.0 billion and ROE of at least 10%—the company achieved ¥125.5 billion, ¥122.5 billion and 18.6%, respectively, in FY2019, primarily driven by the growth of the anticancer drug Lenvima, achieving all targets one year ahead of schedule.」
The operating profit, profit for the year and ROE targets for FY2020, the midpoint of EWAY 2025, were achieved one year ahead of schedule in FY2019. - FY2019RestatedAnnual report
「While responding to changes in the environment surrounding pharmaceutical companies, the group aims to help resolve social issues through the implementation of its medium-term management plan, “EWAY 2025.”」
EWAY 2025 continues to link responses to environmental change with efforts to resolve social issues. - FY2018RestatedAnnual report
「While responding to changes in the environment surrounding pharmaceutical companies, the group is working steadily to realize its medium-term management plan, “EWAY 2025.”」
The group has reaffirmed its commitment to EWAY 2025 and to steadily implementing the plan while responding to changes in the environment. - FY2017RestatedAnnual report
「While responding flexibly to changes in the external environment surrounding pharmaceutical companies, the group aims to realize the strategic objectives of “EWAY 2025.”」
The group continues to pursue EWAY 2025 and its strategic objectives toward 2025. - FY2016First statedAnnual report
「We formulated a new medium-term management plan, “EWAY 2025,” through 2025, and launched it in April 2016.」
The plan sets out the goal of meeting hhc needs in two critical domains toward FY2025: “prevention, cure and care,” and “community healthcare that delivers peace of mind and safety.”